ArticleNeuro-oncology advances
MR1 overexpression correlates with poor clinical prognosis in glioma patients.
Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 16 citations in OpenAlex.
- Review
- Select intratumoral riboflavin-auxotrophicProceedings of the National Academy of Sciences of the United States of America · 2026Article
- Brain-Resident MAIT Cells Infiltrate GL261 Tumors, and Activated MAIT Cell Signatures Are Associated With Improved Outcomes in Glioma.Neurology(R) neuroimmunology & neuroinflammation · 2026Article
- Dual Roles of MAIT Cells in the Tumor Microenvironment: Implications for Cancer Immunity and Therapy.Immune network · 2026Review
- Unconventional guardians of the brain: MAIT cells as emerging players in glioblastoma immunity.Frontiers in immunology · 2026Review
- Differential gene expression analysis in French bulldog high grade oligodendroglioma: breed-associated differences in tumor and tumor microenvironment gene expression.Companion animal health and genetics · 2025Article
- IFNγ regulates MR1 transcription and antigen presentation.Frontiers in immunology · 2025Article
- Unconventional T cells in anti-cancer immunity.Frontiers in immunology · 2025Review
- The MR1/MAIT cell axis in CNS diseases.Brain, behavior, and immunity · 2024Review
- Dysfunctional states of unconventional T-cell subsets in cancer.Journal of leukocyte biology · 2024Article
- Role of innate T cells in necrotizing enterocolitis.Frontiers in immunology · 2024Review
- Mucosal-associated invariant T cells in cancer: dual roles, complex interactions and therapeutic potential.Frontiers in immunology · 2024Review
- Article
- Control of the temporal development of Alzheimer's disease pathology by the MR1/MAIT cell axis.Journal of neuroinflammation · 2023Article
- Article
- Characterization of MAIT cells in glioblastoma reveals a potential immunosuppressive role through a MAIT-neutrophil axis.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundGlioblastoma is the most common adult primary brain tumor with near-universal fatality. Major histocompatibility complex (MHC) class I molecules are important mediators of CD8 activation and can be downregulated by cancer cells to escape immune surveillance. MR1 is a nonclassical MHC-I-like molecule responsible for the activation of a subset of T cells. Although high levels of MR1 expression should enhance cancer cell recognition, various tumors demonstrate MR1 overexpression with unknown implications. Here, we study the role of MR1 in glioma.
methodsUsing multi-omics data from the Cancer Genome Atlas (TCGA), we studied
results
conclusionsOur in silico analysis shows that
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.